Best Therapeutic Response: Second-Line Therapy Outcomes for Unresectable HCC

A retrospective study comparing second-line therapies for unresectable hepatocellular carcinoma (uHCC) after first-line atezolizumab plus bevacizumab. The dataset contains real-world data from 81 patients, with 14 receiving durvalumab plus tremelimumab and 67 receiving lenvatinib. It was authored by Chinatsu Nishioka and last updated in May 2026.

Use Cases

• Compare progression-free survival (PFS) and overall survival (OS) between two second-line therapy regimens.
• Analyze adverse event (AE) frequency and severity for lenvatinib versus durvalumab plus tremelimumab.
• Model predictors of survival based on variables like neutrophil-to-lymphocyte ratio mentioned in the description.
• Assess changes in liver function using the albumin–bilirubin (ALBI) score over time.

Strengths

• Includes specific clinical outcome metrics: objective response rates (7.7% vs 23.3%) and disease control rates (15.4% vs 76.7%).
• Reports key survival statistics: median PFS (1.7 vs 4.2 months) and median OS (5.3 vs 14.0 months).
• Contains detailed adverse event data, including frequency of Grade ≥3 AEs (21.4% vs 70.1%).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), indicating limited scope and sample size.

Provenance

Source

figshare, authored by Chinatsu Nishioka.

Collection Method

Retrospective analysis of a prospectively registered observational cohort.

Time Range

null

Freshness

Last updated 2026-05-07 18:00:13; freshness should be verified.

Geography

null